Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Acute mountain sickness and high altitude cerebral edema

Scott A Gallagher, MD
Peter Hackett, MD
Section Editor
Daniel F Danzl, MD
Deputy Editor
Jonathan Grayzel, MD, FAAEM


Anyone who travels to high altitude, whether a recreational hiker, professional mountain climber, or rescue worker, is at risk of developing high altitude illness. Acute mountain sickness (AMS) and high altitude cerebral edema (HACE) represent a continuum of one form of such illness.

The pathophysiology, clinical presentation, treatment, and prevention of AMS and HACE are reviewed here. Other forms of high altitude illness are discussed separately. (See "High altitude pulmonary edema" and "High altitude illness: Physiology, risk factors, and general prevention".)


Acute mountain sickness (AMS) and high altitude cerebral edema (HACE) are generally considered to represent two points along a single spectrum of disease, with the same underlying pathophysiology. Although several aspects of this pathophysiology remain unclear, the concept that AMS/HACE represents a continuum, and that AMS can progress to fatal HACE, fits with clinical experience and is helpful for management. A full discussion of the pathophysiology of AMS and HACE is beyond the scope of this review, but may be found in the attached references [1,2].

Cerebral edema is consistently found in neuroimaging and at autopsy in patients with severe AMS or HACE [1,3,4]. MRI studies reveal reversible vasogenic brain edema, with characteristic T2 signal increase in the splenium of the corpus callosum and subcortical white matter. These findings indicate increased blood-brain barrier (BBB) permeability.

Some hypotheses to explain this increased cerebral vascular permeability emphasize the role of increased intravascular pressure. Increased cerebral blood flow and the loss of autoregulation of intracranial pressure may contribute to such an increase. Chemical factors (eg, vascular endothelial growth factor, nitric oxide, cytokines) may also play a role by altering endothelial permeability [5,6].


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Mar 3, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Wilson MH, Newman S, Imray CH. The cerebral effects of ascent to high altitudes. Lancet Neurol 2009; 8:175.
  2. Bailey DM, Bärtsch P, Knauth M, Baumgartner RW. Emerging concepts in acute mountain sickness and high-altitude cerebral edema: from the molecular to the morphological. Cell Mol Life Sci 2009; 66:3583.
  3. Hackett PH, Yarnell PR, Hill R, et al. High-altitude cerebral edema evaluated with magnetic resonance imaging: clinical correlation and pathophysiology. JAMA 1998; 280:1920.
  4. Severinghaus JW, Chiodi H, Eger EI 2nd, et al. Cerebral blood flow in man at high altitude. Role of cerebrospinal fluid pH in normalization of flow in chronic hypocapnia. Circ Res 1966; 19:274.
  5. Schoene RB. Illnesses at high altitude. Chest 2008; 134:402.
  6. West JB, American College of Physicians, American Physiological Society. The physiologic basis of high-altitude diseases. Ann Intern Med 2004; 141:789.
  7. Kallenberg K, Dehnert C, Dörfler A, et al. Microhemorrhages in nonfatal high-altitude cerebral edema. J Cereb Blood Flow Metab 2008; 28:1635.
  8. Clarke C. Acute mountain sickness: medical problems associated with acute and subacute exposure to hypobaric hypoxia. Postgrad Med J 2006; 82:748.
  9. Dickinson J, Heath D, Gosney J, Williams D. Altitude-related deaths in seven trekkers in the Himalayas. Thorax 1983; 38:646.
  10. Song SY, Asaji T, Tanizaki Y, et al. Cerebral thrombosis at altitude: its pathogenesis and the problems of prevention and treatment. Aviat Space Environ Med 1986; 57:71.
  11. Ross RT. The random nature of cerebral mountain sickness. Lancet 1985; 1:990.
  12. Sanchez del Rio M, Moskowitz MA. High altitude headache. Lessons from headaches at sea level. Adv Exp Med Biol 1999; 474:145.
  13. Murdoch DR. Altitude Illness Among Tourists Flying to 3740 Meters Elevation in the Nepal Himalayas. J Travel Med 1995; 2:255.
  14. Larson EB, Roach RC, Schoene RB, Hornbein TF. Acute mountain sickness and acetazolamide. Clinical efficacy and effect on ventilation. JAMA 1982; 248:328.
  15. Hackett, PH. The Denali Medical Research Project, 1982-1985. Am Alpine J 1986; 28:129.
  16. West JB, Schoene RB, Milledge JS. High Altitude Medicine and Physiology, Hodder Arnold, London 2007.
  17. Hackett PH, Roach RC. High altitude medicine. In: Wilderness Medicine, 5th, Auerbach PS (Ed), Mosby, Philadelphia 2007. p.2.
  18. Schneider M, Bernasch D, Weymann J, et al. Acute mountain sickness: influence of susceptibility, preexposure, and ascent rate. Med Sci Sports Exerc 2002; 34:1886.
  19. Silber E, Sonnenberg P, Collier DJ, et al. Clinical features of headache at altitude: a prospective study. Neurology 2003; 60:1167.
  20. Vann RD, Pollock NW, Pieper CF, et al. Statistical models of acute mountain sickness. High Alt Med Biol 2005; 6:32.
  21. Theis MK, Honigman B, Yip R, et al. Acute mountain sickness in children at 2835 meters. Am J Dis Child 1993; 147:143.
  22. Yaron M, Waldman N, Niermeyer S, et al. The diagnosis of acute mountain sickness in preverbal children. Arch Pediatr Adolesc Med 1998; 152:683.
  23. Wu TY, Ding SQ, Liu JL, et al. Who should not go high: chronic disease and work at altitude during construction of the Qinghai-Tibet railroad. High Alt Med Biol 2007; 8:88.
  24. Dickinson JG. Severe acute mountain sickness. Postgrad Med J 1979; 55:454.
  25. Hackett PH, Rennie D, Levine HD. The incidence, importance, and prophylaxis of acute mountain sickness. Lancet 1976; 2:1149.
  26. Bird BA, Wright AD, Wilson MH, et al. High altitude ataxia--its assessment and relevance. Wilderness Environ Med 2011; 22:172.
  27. Chen HC, Lin WL, Wu JY, et al. Change in oxygen saturation does not predict acute mountain sickness on Jade Mountain. Wilderness Environ Med 2012; 23:122.
  28. O'Connor T, Dubowitz G, Bickler PE. Pulse oximetry in the diagnosis of acute mountain sickness. High Alt Med Biol 2004; 5:341.
  29. Wagner DR, Knott JR, Fry JP. Oximetry fails to predict acute mountain sickness or summit success during a rapid ascent to 5640 meters. Wilderness Environ Med 2012; 23:114.
  30. Karinen HM, Peltonen JE, Kähönen M, Tikkanen HO. Prediction of acute mountain sickness by monitoring arterial oxygen saturation during ascent. High Alt Med Biol 2010; 11:325.
  31. Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness Environ Med 2010; 21:146.
  32. Hackett PH, Roach RC. High-altitude illness. N Engl J Med 2001; 345:107.
  33. Bärtsch P, Baumgartner RW, Waber U, et al. Comparison of carbon-dioxide-enriched, oxygen-enriched, and normal air in treatment of acute mountain sickness. Lancet 1990; 336:772.
  34. Bärtsch P, Merki B, Hofstetter D, et al. Treatment of acute mountain sickness by simulated descent: a randomised controlled trial. BMJ 1993; 306:1098.
  35. Grissom CK, Roach RC, Sarnquist FH, Hackett PH. Acetazolamide in the treatment of acute mountain sickness: clinical efficacy and effect on gas exchange. Ann Intern Med 1992; 116:461.
  36. Hackett PH, Roach RC, Wood RA, et al. Dexamethasone for prevention and treatment of acute mountain sickness. Aviat Space Environ Med 1988; 59:950.
  37. Keller HR, Maggiorini M, Bärtsch P, Oelz O. Simulated descent v dexamethasone in treatment of acute mountain sickness: a randomised trial. BMJ 1995; 310:1232.
  38. Hackett PH, Roach RC. High altitude cerebral edema. High Alt Med Biol 2004; 5:136.
  39. Ferrazzini G, Maggiorini M, Kriemler S, et al. Successful treatment of acute mountain sickness with dexamethasone. Br Med J (Clin Res Ed) 1987; 294:1380.
  40. Levine BD, Yoshimura K, Kobayashi T, et al. Dexamethasone in the treatment of acute mountain sickness. N Engl J Med 1989; 321:1707.
  41. Freeman K, Shalit M, Stroh G. Use of the Gamow Bag by EMT-basic park rangers for treatment of high-altitude pulmonary edema and high-altitude cerebral edema. Wilderness Environ Med 2004; 15:198.
  42. Zafren K. Gamow bag for high-altitude cerebral oedema. Lancet 1998; 352:325.
  43. Houston CS, Dickinson J. Cerebral form of high-altitude illness. Lancet 1975; 2:758.
  44. Forwand SA, Landowne M, Follansbee JN, Hansen JE. Effect of acetazolamide on acute mountain sickness. N Engl J Med 1968; 279:839.
  45. Basnyat B, Gertsch JH, Holck PS, et al. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Alt Med Biol 2006; 7:17.
  46. van Patot MC, Leadbetter G 3rd, Keyes LE, et al. Prophylactic low-dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Alt Med Biol 2008; 9:289.
  47. Pollard AJ, Niermeyer S, Barry P, et al. Children at high altitude: an international consensus statement by an ad hoc committee of the International Society for Mountain Medicine, March 12, 2001. High Alt Med Biol 2001; 2:389.
  48. Ellsworth AJ, Larson EB, Strickland D. A randomized trial of dexamethasone and acetazolamide for acute mountain sickness prophylaxis. Am J Med 1987; 83:1024.
  49. Seupaul RA, Welch JL, Malka ST, Emmett TW. Pharmacologic prophylaxis for acute mountain sickness: a systematic shortcut review. Ann Emerg Med 2012; 59:307.
  50. Low EV, Avery AJ, Gupta V, et al. Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta-analysis. BMJ 2012; 345:e6779.
  51. Kayser B, Dumont L, Lysakowski C, et al. Reappraisal of acetazolamide for the prevention of acute mountain sickness: a systematic review and meta-analysis. High Alt Med Biol 2012; 13:82.
  52. Carlsten C, Swenson ER, Ruoss S. A dose-response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Alt Med Biol 2004; 5:33.
  53. Basnyat B, Gertsch JH, Johnson EW, et al. Efficacy of low-dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial. High Alt Med Biol 2003; 4:45.
  54. Swenson ER. Carbonic anhydrase inhibitors and hypoxic pulmonary vasoconstriction. Respir Physiol Neurobiol 2006; 151:209.
  55. Teppema LJ, Balanos GM, Steinback CD, et al. Effects of acetazolamide on ventilatory, cerebrovascular, and pulmonary vascular responses to hypoxia. Am J Respir Crit Care Med 2007; 175:277.
  56. Hackett PH, Roach RC, Hartig GS, et al. The effect of vasodilators on pulmonary hemodynamics in high altitude pulmonary edema: a comparison. Int J Sports Med 1992; 13 Suppl 1:S68.
  57. Sutton JR, Reeves JT, Wagner PD, et al. Operation Everest II: oxygen transport during exercise at extreme simulated altitude. J Appl Physiol (1985) 1988; 64:1309.
  58. Senay LC Jr, Tolbert DL. Effect of arginine vasopressin, acetazolamide, and angiotensin II on CSF pressure at simulated altitude. Aviat Space Environ Med 1984; 55:370.
  59. Rock PB, Johnson TS, Larsen RF, et al. Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level. Chest 1989; 95:568.
  60. Ellsworth AJ, Meyer EF, Larson EB. Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. West J Med 1991; 154:289.
  61. Bernhard WN, Schalick LM, Delaney PA, et al. Acetazolamide plus low-dose dexamethasone is better than acetazolamide alone to ameliorate symptoms of acute mountain sickness. Aviat Space Environ Med 1998; 69:883.
  62. Hussain MM, Aslam M. Hypoxia and pulmonary acclimatisation at 4578 m altitude: the role of acetazolamide and dexamethasone. J Pak Med Assoc 2003; 53:451.
  63. Rock PB, Johnson TS, Cymerman A, et al. Effect of dexamethasone on symptoms of acute mountain sickness at Pikes Peak, Colorado (4,300 m). Aviat Space Environ Med 1987; 58:668.
  64. Tang E, Chen Y, Luo Y. Dexamethasone for the prevention of acute mountain sickness: systematic review and meta-analysis. Int J Cardiol 2014; 173:133.
  65. Lafleur J, Giron M, Demarco M, et al. Cognitive effects of dexamethasone at high altitude. Wilderness Environ Med 2003; 14:20.
  66. Jobe JB, Shukitt-Hale B, Banderet LE, Rock PB. Effects of dexamethasone and high terrestrial altitude on cognitive performance and affect. Aviat Space Environ Med 1991; 62:727.
  67. Basu M, Sawhney RC, Kumar S, et al. Glucocorticoids as prophylaxis against acute mountain sickness. Clin Endocrinol (Oxf) 2002; 57:761.
  68. Burtscher M, Likar R, Nachbauer W, Philadelphy M. Aspirin for prophylaxis against headache at high altitudes: randomised, double blind, placebo controlled trial. BMJ 1998; 316:1057.
  69. Burtscher M, Likar R, Nachbauer W, et al. Effects of aspirin during exercise on the incidence of high-altitude headache: a randomized, double-blind, placebo-controlled trial. Headache 2001; 41:542.
  70. Broome JR, Stoneham MD, Beeley JM, et al. High altitude headache: treatment with ibuprofen. Aviat Space Environ Med 1994; 65:19.
  71. Lipman GS, Kanaan NC, Holck PS, et al. Ibuprofen prevents altitude illness: a randomized controlled trial for prevention of altitude illness with nonsteroidal anti-inflammatories. Ann Emerg Med 2012; 59:484.
  72. Gertsch JH, Corbett B, Holck PS, et al. Altitude Sickness in Climbers and Efficacy of NSAIDs Trial (ASCENT): randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness. Wilderness Environ Med 2012; 23:307.
  73. Gertsch JH, Basnyat B, Johnson EW, et al. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ 2004; 328:797.